东方红医疗升级股票发起A（015052）基金经理为江琦。 截至发稿，江琦累计任职时间3年168天，现任基金资产总规模14.1亿元，任职期间最佳基金回报 70.01%， 任职期间最差基金回报67.12%。 从基金十大重仓股角度 数据显示，东证资管旗下1只基金重仓智翔金泰。东方红医疗升级股票发起A（015052）二季度减持9.27 万股，持有股数245.12万股，占基金净值比例为4.82%，位居第八大重仓股。根据测算，今日浮亏损失 约463.27万元。 9月11日，智翔金泰跌5.61%，截至发稿，报31.80元/股，成交3182.69万元，换手率0.84%，总市值 116.60亿元。 资料显示，重庆智翔金泰生物制药股份有限公司位于重庆市巴南区麻柳大道699号2号楼A区，成立日期 2015年10月20日，上市日期2023年6月20日，公司主营业务涉及抗体药物的研发、生产与销售。主营业 务收入构成为：销售药品99.96%，其他0.04%。 从智翔金泰十大流通股东角度 数据显示，东证资管旗下1只基金位居智翔金泰十大流通股东。东方红医疗升级股票发起A（015052） 二季度减持9.27万股，持有股数245.12万股，占流 ...

Core Insights - The latest public fund reports reveal significant growth in the asset management scale of brokerage firms, with top firms exceeding 100 billion yuan in management scale [2][3]. Group 1: Asset Management Scale - As of the end of Q2 2025, four brokerage asset management firms have surpassed 100 billion yuan in public fund assets, with Dongfanghong Asset Management leading at 179.84 billion yuan [3][4]. - Other top firms include Huatai Securities Asset Management at 165.11 billion yuan, Zhongyin International Securities at 130.31 billion yuan, and Caitong Securities Asset Management at 113.61 billion yuan [3][4]. - Compared to the end of Q1 2025, the asset management scale of leading brokerage firms has generally increased, with Dongfanghong and Huatai Securities both growing by over 20 billion yuan [3]. Group 2: Fund Manager Performance - In the first half of the year, the A-share market was active, leading to strong performance from equity fund managers, with notable net value increases in their products [5]. - For instance, the Dongfanghong Medical Upgrade Stock Fund managed by Jiang Qi saw a net value growth of 44.55% in the first half of the year, reaching a new high since its inception [5][6]. - Fund managers are optimistic about the innovation drug sector, with strategies focusing on biopharmaceuticals and increased allocations to innovative drugs in the Hong Kong and STAR markets [6]. Group 3: Market Outlook - Fund managers express a positive long-term outlook, citing the transition to a low-interest-rate environment and the potential for wealth to shift from savings to equity assets [6]. - The anticipated economic slowdown may lead to a systematic increase in return on equity (ROE), supporting a long-term bullish trend in Chinese assets [6]. - The performance of certain cyclical industries has been mixed, but overall macroeconomic sentiment remains optimistic [7].

Core Viewpoint - The article discusses the recent disclosure of public fund second-quarter reports by securities asset management firms, highlighting the growth in asset management scale and insights from fund managers [2][3]. Group 1: Asset Management Scale - As of the end of Q2 2025, four securities asset management firms have surpassed a public fund asset management scale of 100 billion yuan, with Dongfanghong Asset Management leading at 179.84 billion yuan, followed by Huatai Securities Asset Management at 165.11 billion yuan, and Zhongyin Securities at 130.31 billion yuan [4]. - Compared to the end of Q1 2025, the top securities asset management firms have generally experienced growth in public fund management scale, with Dongfanghong and Huatai Securities increasing by over 20 billion yuan each, and招商证券 growing by 3.3 billion yuan [4]. Group 2: Fund Manager Insights - The A-share market has been active in the first half of the year, with securities asset management fund managers generally reporting good performance and rising product net values [6]. - Jiang Qi, the fund manager of Dongfanghong Medical Upgrade Stock A, reported a net value increase of 44.55% in the first half of the year, reaching a new high since its inception [7]. - Jiang Qi maintains a high stock position of 90.37% and has increased allocations to innovative drugs in the Hong Kong and Sci-Tech Innovation Board markets, indicating a strong belief in the growth of the innovative drug sector [7]. - Zhou Yun, managing the Dongfanghong JD Big Data Mixed Fund, noted a net value increase of 6.55% in the first half of the year, emphasizing the long-term impact of low interest rates and the shift of household wealth towards equity assets [8]. - Jiang Cheng, Deputy General Manager of Zhongtai Asset Management, reported that his product's net value has increased over 108% in the past five years, while expressing a cautious outlook on individual stocks despite a generally optimistic macroeconomic view [9][10].

Core Viewpoint - The article highlights the strong performance of public equity funds managed by various asset management firms in the first half of the year, particularly in sectors like AI, robotics, and innovative pharmaceuticals, with several fund managers achieving record net asset values [2][4]. Group 1: Fund Performance - In the first half of the year, the A-share market was active, with significant performances in sectors such as AI, robotics, and innovative pharmaceuticals [2]. - The net asset value of the "Oriental Red Medical Upgrade Stock Initiation A" fund managed by Jiang Qi increased by 44.55%, reaching a new high since its inception [2][4]. - Jiang Qi's fund maintained a high stock position of 90.37% as of June 30, with top holdings including Bai Li Tianheng and Kanghong Pharmaceutical [4]. Group 2: Manager Insights - Jiang Qi believes that the innovative pharmaceutical sector is entering a harvest phase, with expectations for a prolonged period of growth [5]. - Jiang Qi emphasizes the importance of technological advancements and clinical resources in accelerating the development of innovative pharmaceutical companies [5][6]. - Zhou Yun from Oriental Red Asset Management notes that the low interest rate environment and the "anti-involution" trend support a long-term bullish outlook for Chinese assets [7]. Group 3: Market Outlook - Jiang Cheng from Zhongtai Asset Management expresses a cautious optimism regarding macroeconomic conditions while advising caution at the micro level [8]. - Tian Yu from Zhongtai Asset Management remains optimistic about high-end liquor, citing business demand as a key driver despite recent market concerns [9].